Sumitomo Mitsui Trust Group
SRPT icon

Sumitomo Mitsui Trust Group’s Sarepta Therapeutics SRPT Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,930
Closed -$235K – 1063
2024
Q4 		$235K Buy
1,930
+230
+14% +$28.2K ﹤0.01% 1017
2024
Q3 		$212K Buy
1,700
+300
+21% +$41.5K ﹤0.01% 1038
2024
Q2 		$221K Sell
1,400
-2,981
-68% -$383K ﹤0.01% 1044
2024
Q1 		$567K Sell
4,381
-2,271
-34% -$278K ﹤0.01% 1010
2023
Q4 		$641K Sell
6,652
-1,340
-17% -$129K ﹤0.01% 1021
2023
Q3 		$969K Buy
7,992
+2,172
+37% +$245K ﹤0.01% 989
2023
Q2 		$667K Sell
5,820
-702
-11% -$90.5K ﹤0.01% 1034
2023
Q1 		$899K Sell
6,522
-2,783
-30% -$361K ﹤0.01% 1012
2022
Q4 		$1.21M Sell
9,305
-81
-0.9% -$9.39K ﹤0.01% 1002
2022
Q3 		$1.04M Sell
9,386
-2,096
-18% -$211K ﹤0.01% 1028
2022
Q2 		$861K Sell
11,482
-196
-2% -$14.4K ﹤0.01% 1062
2022
Q1 		$912K Sell
11,678
-548
-4% -$42K ﹤0.01% 1055
2021
Q4 		$1.1M Sell
12,226
-476
-4% -$40.7K ﹤0.01% 1018
2021
Q3 		$1.18M Sell
12,702
-19,314
-60% -$1.49M ﹤0.01% 1011
2021
Q2 		$2.49M Sell
32,016
-415,139
-93% -$31.5M ﹤0.01% 926
2021
Q1 		$33.3M Buy
447,155
+114,642
+34% +$10.6M 0.02% 635
2020
Q4 		$56.7M Sell
332,513
-3,126
-0.9% -$463K 0.04% 487
2020
Q3 		$47.1M Sell
335,639
-47,952
-13% -$7.29M 0.03% 502
2020
Q2 		$61.5M Sell
383,591
-26,893
-7% -$3.66M 0.04% 432
2020
Q1 		$40.2M Buy
410,484
+6,246
+2% +$714K 0.03% 497
2019
Q4 		$52.2M Sell
404,238
-1,094
-0.3% -$110K 0.04% 467
2019
Q3 		$30.5M Buy
405,332
+317,840
+363% +$37.5M 0.03% 575
2019
Q2 		$13.3M Buy
87,492
+45,024
+106% +$5.47M 0.01% 704
2019
Q1 		$5.06M Buy
+42,468
New +$5.46M ﹤0.01% 723

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group's SRPT Position: Q1 2025 in Review

Sumitomo Mitsui Trust Group sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 1,930 shares — an estimated $235K sold.

Sumitomo Mitsui Trust Group first reported a position in SRPT in Q1 2019 and held it in 24 quarters. The position peaked at $61.5M in Q2 2020. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Sumitomo Mitsui Trust Group reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 1,930 Sarepta Therapeutics shares in Q1 2025, an estimated $235K.
  • Sumitomo Mitsui Trust Group first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 24 quarters.
  • Sumitomo Mitsui Trust Group's Sarepta Therapeutics position peaked at $61.5M in Q2 2020.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q1 2025, filed 25 Apr 2025.